Nondzakazi Mnqonywa
Project Manager
Nondzakazi has been working as a Project Manager for the Aurum Institute based in South Africa since 2017. She holds a MMedSc (2018) and as part of her studies, participated in the Research Participation Program at the Center for Biological Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA) administered by Oak Ridge Institute for Science and Education (ORISE).
She has worked in clinical trials since 2004 with the South African Medical Research Council and has extensive knowledge about HIV and TB in Clinical Trials. Additionally, she is involved in training and supervision of research teams and performance management and ensuring that staff conduct the trial ethically with Good Clinical Practice (GCP) and ensuring that Standard Operating Procedures (SOPs) are followed adequately.
She has worked in several Phase II and III randomized controlled clinical trials investigating various antiretroviral regimens to prevent HIV infection (Microbicides). These clinical trials have culminated in key scientific publications that served as a benchmark for further advances in HIV prevention. She has one scientific publication (1st author), “Exploring the immunomodulatory role of depot medroxyprogesterone acetate and endogenous progesterone levels in HIV infected and uninfected women. Mnqonywa et al. BMC Res Notes (2019) 12:745”. She has also contributed to international scientific presentations.
She has worked in clinical trials since 2004 with the South African Medical Research Council and has extensive knowledge about HIV and TB in Clinical Trials. Additionally, she is involved in training and supervision of research teams and performance management and ensuring that staff conduct the trial ethically with Good Clinical Practice (GCP) and ensuring that Standard Operating Procedures (SOPs) are followed adequately.
She has worked in several Phase II and III randomized controlled clinical trials investigating various antiretroviral regimens to prevent HIV infection (Microbicides). These clinical trials have culminated in key scientific publications that served as a benchmark for further advances in HIV prevention. She has one scientific publication (1st author), “Exploring the immunomodulatory role of depot medroxyprogesterone acetate and endogenous progesterone levels in HIV infected and uninfected women. Mnqonywa et al. BMC Res Notes (2019) 12:745”. She has also contributed to international scientific presentations.
Contact
Email Groups
| Email Group Address | Description |
|---|---|
| matrixcase2022scholars@lists.matrix4prevention.org | CaSE 2022 Scholars |
| matrixcollaborators@matrix4prevention.org | MATRIX Collaborators (excludes SAG and USAID) |